397 related articles for article (PubMed ID: 17466590)
1. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.
Pier GB
Int J Med Microbiol; 2007 Sep; 297(5):277-95. PubMed ID: 17466590
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa antigens as potential vaccines.
Stanislavsky ES; Lam JS
FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
[TBL] [Abstract][Full Text] [Related]
3. Review: Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa.
King JD; Kocíncová D; Westman EL; Lam JS
Innate Immun; 2009 Oct; 15(5):261-312. PubMed ID: 19710102
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa lipid A diversity and its recognition by Toll-like receptor 4.
Ernst RK; Hajjar AM; Tsai JH; Moskowitz SM; Wilson CB; Miller SI
J Endotoxin Res; 2003; 9(6):395-400. PubMed ID: 14733728
[TBL] [Abstract][Full Text] [Related]
5. A Pseudomonas aeruginosa hepta-acylated lipid A variant associated with cystic fibrosis selectively activates human neutrophils.
SenGupta S; Hittle LE; Ernst RK; Uriarte SM; Mitchell TC
J Leukoc Biol; 2016 Nov; 100(5):1047-1059. PubMed ID: 27538572
[TBL] [Abstract][Full Text] [Related]
6. Presence or absence of lipopolysaccharide O antigens affects type III secretion by Pseudomonas aeruginosa.
Augustin DK; Song Y; Baek MS; Sawa Y; Singh G; Taylor B; Rubio-Mills A; Flanagan JL; Wiener-Kronish JP; Lynch SV
J Bacteriol; 2007 Mar; 189(6):2203-9. PubMed ID: 17209027
[TBL] [Abstract][Full Text] [Related]
7. Structural diversity of the core oligosaccharide domain of Pseudomonas aeruginosa lipopolysaccharide.
Kocíncová D; Lam JS
Biochemistry (Mosc); 2011 Jul; 76(7):755-60. PubMed ID: 21999536
[TBL] [Abstract][Full Text] [Related]
8. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
9. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa.
Ernst RK; Yi EC; Guo L; Lim KB; Burns JL; Hackett M; Miller SI
Science; 1999 Nov; 286(5444):1561-5. PubMed ID: 10567263
[TBL] [Abstract][Full Text] [Related]
10. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
Kronborg G
APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa lipopolysaccharides and pathogenesis.
Goldberg JB; Pler GB
Trends Microbiol; 1996 Dec; 4(12):490-4. PubMed ID: 9004407
[TBL] [Abstract][Full Text] [Related]
12. Persistent cystic fibrosis isolate Pseudomonas aeruginosa strain RP73 exhibits an under-acylated LPS structure responsible of its low inflammatory activity.
Di Lorenzo F; Silipo A; Bianconi I; Lore' NI; Scamporrino A; Sturiale L; Garozzo D; Lanzetta R; Parrilli M; Bragonzi A; Molinaro A
Mol Immunol; 2015 Feb; 63(2):166-75. PubMed ID: 24856407
[TBL] [Abstract][Full Text] [Related]
13. Polysaccharide antigens of Pseudomonas aeruginosa.
Knirel YA
Crit Rev Microbiol; 1990; 17(4):273-304. PubMed ID: 1698385
[TBL] [Abstract][Full Text] [Related]
14. Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen.
Pier GB
Carbohydr Res; 2003 Nov; 338(23):2549-56. PubMed ID: 14670716
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody S60-4-14 reveals diagnostic potential in the identification of Pseudomonas aeruginosa in lung tissues of cystic fibrosis patients.
Schmengler K; Goldmann T; Brade L; Sánchez Carballo PM; Albrecht S; Brade H; Kosma P; Sahly H; Hauber HP; Länger F; Meyer R; Welte T; Zähringer U
Eur J Cell Biol; 2010 Jan; 89(1):25-33. PubMed ID: 20022136
[TBL] [Abstract][Full Text] [Related]
16. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation.
Schroeder TH; Lee MM; Yacono PW; Cannon CL; Gerçeker AA; Golan DE; Pier GB
Proc Natl Acad Sci U S A; 2002 May; 99(10):6907-12. PubMed ID: 11997458
[TBL] [Abstract][Full Text] [Related]
17. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
[TBL] [Abstract][Full Text] [Related]
18. Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa.
Rocchetta HL; Burrows LL; Lam JS
Microbiol Mol Biol Rev; 1999 Sep; 63(3):523-53. PubMed ID: 10477307
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors in the host defense against Pseudomonas aeruginosa respiratory infection and cystic fibrosis.
McIsaac SM; Stadnyk AW; Lin TJ
J Leukoc Biol; 2012 Nov; 92(5):977-85. PubMed ID: 22892106
[TBL] [Abstract][Full Text] [Related]
20. Human Toll-like receptor 4 recognizes host-specific LPS modifications.
Hajjar AM; Ernst RK; Tsai JH; Wilson CB; Miller SI
Nat Immunol; 2002 Apr; 3(4):354-9. PubMed ID: 11912497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
